Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Centus Biotherapeutics
Centus Biotherapeutics
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Equidacent
Bevacizumab
2020-09-24
Renal cell carcinoma
,
Colorectal neoplasms
,
Breast neoplasms
,
Ovarian neoplasms
,
Non-small-cell lung carcinoma
,
Glioblastoma
,
Fallopian tube neoplasms
,
Kidney neoplasms
,
Uterine cervical neoplasms
,
Peritoneal neoplasms
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Bevacizumab
lung neoplasms
,
pancreatic ductal carcinoma
,
hepatocellular carcinoma
,
esophageal neoplasms
,
gastrointestinal stromal tumors
,
pharmacokinetics
,
healthy volunteers/patients
,
melanoma
,
non-muscle invasive bladder neoplasms
,
glioblastoma
,
adenocarcinoma
,
carcinoma
,
liver neoplasms
,
stomach neoplasms
,
triple negative breast neoplasms
,
endometrial neoplasms
,
diabetes mellitus
,
diabetic retinopathy
,
residual neoplasm
,
recurrence
,
multiple myeloma
,
colorectal neoplasms
,
non-small-cell lung carcinoma
,
renal cell carcinoma
,
breast neoplasms
,
colonic neoplasms
,
rectal neoplasms
,
digestive system neoplasms
,
neoplasm metastasis
,
ovarian neoplasms
,
ovarian epithelial carcinoma
,
gastrointestinal neoplasms
,
rectal diseases
,
gastrointestinal diseases
,
intestinal neoplasms
,
digestive system diseases
,
colonic diseases
,
intestinal diseases
,
kidney neoplasms
,
urogenital neoplasms
,
neoplasms by site
,
neoplasms
,
macular degeneration
,
macular edema
,
edema
,
choroidal neovascularization
,
pathologic neovascularization
,
fallopian tube neoplasms
,
uterine cervical neoplasms
,
hemorrhage
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use